newsfilter
← Latest News
Business Wire·

Xencor Announces Extension of U.S. Patent Term on Certain Xtend™ Antibodies

-- Royalty term on Ultomiris® sales in the United States anticipated to continue into year-end 2028, extending term by three years -- -- Additional $100 million to $120 million in potential royalty revenue